Results 221 to 230 of about 36,968 (260)
Some of the next articles are maybe not open access.
Rheumatic Disease Clinics of North America, 2012
Bisphosphonates are antiresorptive medications widely prescribed for treating osteoporosis. In placebo-controlled clinical trials they have been shown to significantly reduce the risk of osteoporotic fractures. However, reports of atypical femoral fractures and osteonecrosis of the jaw have emerged with long-term use, raising questions regarding their ...
Catalina, Orozco, Naim M, Maalouf
openaire +2 more sources
Bisphosphonates are antiresorptive medications widely prescribed for treating osteoporosis. In placebo-controlled clinical trials they have been shown to significantly reduce the risk of osteoporotic fractures. However, reports of atypical femoral fractures and osteonecrosis of the jaw have emerged with long-term use, raising questions regarding their ...
Catalina, Orozco, Naim M, Maalouf
openaire +2 more sources
Current Medicinal Chemistry, 2002
Bisphosphonates (BP) are pyrophosphate analogs having a P-C-P backbone. The oral bioavailability of BPs is ca. 1%, due to high ionisation at physiological pH. Using the prodrug approach, oral absorption can be increased by masking one or more ionizable groups (clodronate, etidronate), or using a targeting carrier system (alendronate, pamitronate).
openaire +2 more sources
Bisphosphonates (BP) are pyrophosphate analogs having a P-C-P backbone. The oral bioavailability of BPs is ca. 1%, due to high ionisation at physiological pH. Using the prodrug approach, oral absorption can be increased by masking one or more ionizable groups (clodronate, etidronate), or using a targeting carrier system (alendronate, pamitronate).
openaire +2 more sources
Bisphosphonates for Osteoporosis
New England Journal of Medicine, 2010A 67-year-old woman is referred by her primary care physician for treatment of osteoporosis and progressive bone loss. Oral bisphosphonate therapy is recommended. Bisphosphonates suppress bone resorption by interfering with osteoclast activity. Several of these agents have been shown to prevent fractures and increase bone mineral density in patients ...
openaire +2 more sources
Bisphosphonates and atherosclerosis
General Pharmacology: The Vascular System, 2000Bisphosphonates are used for the treatment of bone resorption, hypercalcemia, osteoporosis and Paget's disease. Etidronate, pamidronate and clodronate also inhibit the development of experimental atherosclerosis without altering serum lipid profile. Bisphosphonates inhibit the arterial calcification, lipid accumulation and fibrosis.
openaire +2 more sources
BISPHOSPHONATES IN ORTHOPAEDIC SURGERY
The Journal of Bone and Joint Surgery-American Volume, 2005Bisphosphonates are the most clinically important class of antiresorptive agents available to treat diseases characterized by osteoclast-mediated bone resorption. Currently, seven bisphosphonates have the approval of the United States Food and Drug Administration.
Carol D, Morris, Thomas A, Einhorn
openaire +2 more sources
Journal of Palliative Medicine, 2009
Bisphosphonates have become an important treatment for the palliation of metastatic bone disease. Their increasing use has lead to the recognition of toxicities that can lead to substantial morbidity for the patient with advanced cancer. This case presentation highlights toxicities associated with bisphosphonate use and provides some guidelines on the ...
openaire +2 more sources
Bisphosphonates have become an important treatment for the palliation of metastatic bone disease. Their increasing use has lead to the recognition of toxicities that can lead to substantial morbidity for the patient with advanced cancer. This case presentation highlights toxicities associated with bisphosphonate use and provides some guidelines on the ...
openaire +2 more sources
Current Rheumatology Reports, 2004
Over the past 15 years, bisphosphonates have been demonstrated as effective therapy for the treatment of osteoporosis based on their ability to suppress bone turnover resulting in increased bone mineral content and increased bone strength. The mechanism of action at the cellular level has been identified, and the more potent nitrogen-containing ...
openaire +2 more sources
Over the past 15 years, bisphosphonates have been demonstrated as effective therapy for the treatment of osteoporosis based on their ability to suppress bone turnover resulting in increased bone mineral content and increased bone strength. The mechanism of action at the cellular level has been identified, and the more potent nitrogen-containing ...
openaire +2 more sources
Bisphosphonate Treatment of Osteoporosis
Clinics in Geriatric Medicine, 2000Bisphosphonates represent the agents of choice for most patients with osteoporosis. They are the best studied of all agents for the prevention of bone loss and reduction in fractures. They increase BMD, primarily at the lumbar spine, but also at the proximal femur.
openaire +2 more sources
TREATMENT OF OSTEOPOROSIS WITH BISPHOSPHONATES
Rheumatic Disease Clinics of North America, 1994Several bisphosphonates are effective for preventing bone loss associated with estrogen deficiency, glucocorticoid treatment, and immobilization, and for at least partially reversing bone loss in patients with postmenopausal osteoporosis and steroid-induced osteoporosis.
openaire +4 more sources